Complicating cure: How Australian criminal law shapes imagined post‐hepatitis C futures

In recent years, highly tolerable and effective drugs have emerged promising a radical new 'post-hepatitis C' world. Optimism about medical cure potentially overlooks discrimination and stigma associated with hepatitis C and injecting drug use. Legal frameworks are especially relevant to hepatitis futures, since the law has the potential to reinforce or alleviate stigma and discrimination. This article explores how hepatitis C figures in Australian criminal law and with what potential effects. Drawing on Bruno Latour's work on legal veridiction, Alison Kafer's work on futurity and disability and case law data collected for a major study on hepatitis C and post-cure lives, we explore how the criminal law handles hepatitis C in the age of cure. We find that law complicates cure, constituting hepatitis C as disabling despite the advent of effective cures. The law steadfastly maintains its own approach to disease, disability and illness, untouched by medical and scientific developments, in ways that might complicate straightforwardly linear imaginaries of cure, transformation and progress of the kind that dominate biomedicine. We explore the implications of these tensions between law and medicine.

[1]  K. Seear,et al.  Echoes and Antibodies: Legal Veridiction and the Emergence of the Perpetual Hepatitis C Subject , 2022, Social & Legal Studies.

[2]  G. Dore Elimination of hepatitis C in Australia by 2030: a decade and counting , 2021, Australian prescriber.

[3]  K. Seear,et al.  Beyond a 'post-cure' world: Sketches for a new futurology of hepatitis C. , 2021, The International journal on drug policy.

[4]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[5]  M. Hellard,et al.  Improving hepatitis C direct‐acting antiviral access and uptake: A role for patient‐reported outcomes and lived experience , 2018, Journal of viral hepatitis.

[6]  M. Harris Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. , 2017, The International journal on drug policy.

[7]  M. Hellard,et al.  Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. , 2017, The International journal on drug policy.

[8]  K. R. Reddy,et al.  Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy , 2016, Alimentary pharmacology & therapeutics.

[9]  C. Rice,et al.  Hepatitis C: Treatment triumphs , 2014, Nature.

[10]  Raymond T Chung,et al.  Curing chronic hepatitis C--the arc of a medical triumph. , 2014, The New England journal of medicine.

[11]  C. Treloar,et al.  The Experience of Interferon-Based Treatments for Hepatitis C Infection , 2005, Qualitative health research.